The Molecular and Translational Imaging Core (MTIC) fills a critical need for the Robert H. Lurie Comprehensive Cancer Center by providing a focus for all cancer imaging research and its clinical application in uniquely well-equipped and designed facilities that straddle the clinical and basic cancer research communities at Northwestern University. The core offers investigators access to a large scope of known imaging modalities, including 1.5, 3, 7 and 9 T MRIs, IVIS Spectrum for in vivo bioluminescence and fluorescence imaging, optical imaging, and X-ray digital subtraction angiography, as well as new imaging technologies developed within the core. The core features one ofthe most advanced 3-D visualization displays in the world along with the expertise required to manipulate and interpret image data. These unique capabilities are central to the advancement of efforts to understand and integrate cellular architecture, flow of information, regulation, and communication across length scales and their impact on tumorigenesis, metastasis, and response to treatment. The Imaging Core is closely intercalated with the Developmental Therapeutics Core and ChemCore, thereby providing cancer researchers with an efficient pipeline for developing, testing, and imaging new diagnostics and therapeutics. The Molecular and Translational Imaging Core will continue to catalyze the development of innovative new imaging technologies for the broad-scale interrogation of disease processes, guidance of therapeutic interventions, and the study human physiology and function. It will continue to provide unique educational opportunities thus fostering efficient, effective utilization of these valuable resources while training the next generation of clinicians, biomedical scientists and engineers. These services are integral to major NCI sponsored research efforts at Northwestern including the Center for Cancer Nanotechnology Excellence, a Cancer Nano Platform Program, and the Physical Sciences-Oncology Center

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8

Showing the most recent 10 out of 316 publications